Navigation Links
U.S. Court of Appeals Rules That Smith & Nephew Does Not Infringe KCI Patents
Date:2/2/2009

ST. PETERSBURG, Fla., Feb. 2 /PRNewswire-FirstCall/ -- Smith & Nephew's Advanced Wound Management division (LSE: SN; NYSE: SNN) today announced that the U.S. Court of Appeals for the Federal Circuit upheld a trial court judgment that the gauze-based Versatile 1 negative pressure wound therapy system marketed by Blue Sky does not infringe KCI's patents. Smith & Nephew acquired Blue Sky in May 2007.

"Smith & Nephew welcomes the appeals court decision today that our Versatile 1 negative pressure wound therapy system does not infringe KCI's patents," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew. "Today's decision affirmed our long-held belief that our gauze-based systems are a legitimate offering in the broader NPWT market. Smith & Nephew will continue operating in this important space. Most importantly, we remain dedicated to using innovative technologies to improve patients' live."

For more information regarding Smith & Nephew, please visit our Web site at www.smith-nephew.com.

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


'/>"/>
SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
2. Its Cold Outside! Warm Up in Select Downtown Boston Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids
3. Its Cold Outside! Warm Up in Select Downtown Chicago Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids
4. Boston Scientific Announces Court Decision
5. Med-Emerg International Inc. receives court approval for AIM Health Group arrangement
6. Blue Cross Wins in Court
7. QLT Announces Appeal Court Decision on Massachusetts Eye and Ear Infirmary Litigation
8. U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health
9. Americans United For Life Denounces Montana Courts Assisted Suicide Decision, Urges Appeal
10. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
11. Top NY Court Blinks in First Department WPP Discrimination Power Play
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology: